6 research outputs found
CANCER PATIENTS FOLLOW-UP ā CROATIAN SOCIETY OF MEDICAL ONCOLOGY CLINICAL GUIDELINES Part III: neuroendocrine neoplasms, hepatocellular carcinoma, pancreatic cancer, cancer of the bile ducts
LijeÄenje onkoloÅ”kih bolesnika mora se temeljiti na multidisciplinarnom pristupu, a provodi se u specijaliziranim onkoloÅ”kim centrima. Nakon zavrÅ”etka specifiÄnog onkoloÅ”kog lijeÄenja daljnje praÄenje uglavnom provode onkolozi, ali je uloga lijeÄnika primarne zdravstvene zaÅ”tite (PZZ) sve važnija i potrebno ju je jasno definirati. TrenutaÄno se veÄina preporuka za praÄenje ne temelji na prospektivnim studijama, veÄ se zasniva na struÄnim miÅ”ljenjima pojedinih onkoloÅ”kih centara ili specijalista. Hrvatsko druÅ”tvo za internistiÄku onkologiju (HDIO) ovim preporukama želi standardizirati i racionalizirati dijagnostiÄke postupke u praÄenju onkoloÅ”kih bolesnika, nakon zavrÅ”etka primarnog lijeÄenja, u bolesnika s neuroendokrinim neoplazmama, hepatocelularnim karcinomom, rakom guÅ”teraÄe i rakom žuÄnih vodova.The treatment of oncological patients must be based upon multidisciplinary approach, and takes place in specialized oncological centers. By the end of a specific oncological treatment further follow-up is being managed mostly by the oncologists, but the role of the general practitioners becomes more important every day and therefore should be precisely defined. Nowadays, most of the existing follow-up guidelines are not based on prospective studies, but on the experts opinion of individual oncological centers or specialists. The aim of the Croatian Society of Medical Oncology (CSMO) with these recommendations is to standardize and rationalize the diagnostic procedures algorithm in the follow-up of oncological patients after primary treatment, in patients with neuroendocrine neoplasms, hepatocellular carcinoma, pancreatic cancer and cancer of the bile ducts
PraÄenje onkoloÅ”kih bolesnika ā kliniÄke preporuke Hrvatskog druÅ”tva za internistiÄku onkologiju HLZ-a III. dio: neuroendokrine neoplazme, hepatocelularni karcinom, rak guÅ”teraÄe, rak žuÄnih vodova [Cancer patients follow-up ā Croatian society of medical oncology clinical guidelines Part III: neuroendocrine neoplasms, hepatocellular carcinoma, pancreatic cancer, cancer of the bile ducts]
The treatment of oncological patients must be based upon multidisciplinary approach, and takes place in specialized oncological centers. By the end of a specific oncological treatment further follow-up is being managed mostly by the oncologists, but the role of the general practitioners becomes more important every day and therefore should be precisely defined. Nowadays, most of the existing follow-up guidelines are not based on prospective studies, but on the experts opinion of individual oncological centers or specialists. The aim of the Croatian Society of Medical Oncology (CSMO) with these recommendations is to standardize and rationalize the diagnostic procedures algorithm in the follow-up of oncological patients after primary treatment, in patients with neuroendocrine neoplasms, hepatocellular carcinoma, pancreatic cancer and cancer of the bile ducts
CANCER PATIENTS FOLLOW-UP ā CROATIAN SOCIETY OF MEDICAL ONCOLOGY CLINICAL GUIDELINES Part III: neuroendocrine neoplasms, hepatocellular carcinoma, pancreatic cancer, cancer of the bile ducts
LijeÄenje onkoloÅ”kih bolesnika mora se temeljiti na multidisciplinarnom pristupu, a provodi se u specijaliziranim onkoloÅ”kim centrima. Nakon zavrÅ”etka specifiÄnog onkoloÅ”kog lijeÄenja daljnje praÄenje uglavnom provode onkolozi, ali je uloga lijeÄnika primarne zdravstvene zaÅ”tite (PZZ) sve važnija i potrebno ju je jasno definirati. TrenutaÄno se veÄina preporuka za praÄenje ne temelji na prospektivnim studijama, veÄ se zasniva na struÄnim miÅ”ljenjima pojedinih onkoloÅ”kih centara ili specijalista. Hrvatsko druÅ”tvo za internistiÄku onkologiju (HDIO) ovim preporukama želi standardizirati i racionalizirati dijagnostiÄke postupke u praÄenju onkoloÅ”kih bolesnika, nakon zavrÅ”etka primarnog lijeÄenja, u bolesnika s neuroendokrinim neoplazmama, hepatocelularnim karcinomom, rakom guÅ”teraÄe i rakom žuÄnih vodova.The treatment of oncological patients must be based upon multidisciplinary approach, and takes place in specialized oncological centers. By the end of a specific oncological treatment further follow-up is being managed mostly by the oncologists, but the role of the general practitioners becomes more important every day and therefore should be precisely defined. Nowadays, most of the existing follow-up guidelines are not based on prospective studies, but on the experts opinion of individual oncological centers or specialists. The aim of the Croatian Society of Medical Oncology (CSMO) with these recommendations is to standardize and rationalize the diagnostic procedures algorithm in the follow-up of oncological patients after primary treatment, in patients with neuroendocrine neoplasms, hepatocellular carcinoma, pancreatic cancer and cancer of the bile ducts
Mjesto i važnost nekliniÄkih bolniÄkih centara u lijeÄenju bolesnika sa zloÄudnim bolestima u Republici Hrvatskoj
Onkologija predstavlja važan segment sveukupnoga hrvatskoga zdravstvenog sustava. Sama onkologija
jedna je od trenutaÄno najpropulzivnijih medicinskih struka te smo svakodnevno svjedoci ekspanzivnog rasta
novih modaliteta onkoloÅ”kog lijeÄenja. Ove Äinjenice nameÄu imperativ stvaranja onkoloÅ”ke mreže koja bi kao
zadatak imala standardiziranje onkoloÅ”kog lijeÄenja i osiguravanje dostupnosti novih modaliteta lijeÄenja za sve
oboljele od zloÄudnih bolesti, neovisno o njihovom mjestu boravka.Ā¹ Hrvatska veÄ ima prepoznate i definirane
regionalne onkoloÅ”ke centre u sklopu kliniÄkih bolniÄkih centara u Zagrebu, Rijeci, Osijeku i Splitu. NasreÄu, u
Hrvatskoj postoji tradicija, stara nekoliko desetljeÄa, razvoja onkoloÅ”kih centara u opÄim i županijskim bolnicama.
Poimence, to su nekliniÄki onkoloÅ”ki centri u Županijskoj bolnici Äakovec, OpÄoj bolnici Dubrovnik, OpÄoj bolnici
Karlovac, OpÄoj bolnici Koprivnica, OpÄoj bolnici Pula, OpÄoj bolnici Slavonski Brod, OpÄoj bolnici Å ibenik, OpÄoj
bolnici Varaždin i OpÄoj bolnici Zadar. Svrha ovoga istraživanja, provedenog u svim nekliniÄkim onkoloÅ”kim
centrima
Hrvatske te koriŔtenjem podataka Državnog zavoda za statistiku i Hrvatskog zavoda za zdravstveno osiguranje,
bila je uvidjeti kako je trenutno organizirana onkoloÅ”ka skrb u Republici Hrvatskoj i koja je uloga nekliniÄkih
onkoloÅ”kih centara u lijeÄenju bolesnika sa zloÄudnim bolestima u Republici Hrvatskoj
Impact of the coronavirus disease pandemic on cancer care in Croatia: a multicentre cross-sectional study
Purpose: The coronavirus disease (COVID-19) pandemic has greatly affected the oncology community worldwide. Lockdowns, an epidemiological measure, have made it difficult for oncologists to provide care. In this study, we analysed the impact of the COVID-19 pandemic on Croatian cancer care.
-----
Methods: This was a multicentre cross-sectional observational study of 422 patients who received systemic oncology therapy during the pandemic. The patients completed a survey to capture their views on the impact of the COVID-19 pandemic on their cancer care. Univariate descriptive and bivariate analyses were performed to analyse the relationship between the patients' perspective on the impact of the COVID-19 pandemic on cancer care and the quality of Croatian cancer care and their clinical and sociodemographic data.
-----
Results: Discontinuation or change in cancer treatment during the COVID-19 pandemic was observed in 10.2% of cases. Most did not change their place of treatment owing to the lockdown (97.6%). 14.7% of the patients felt that the quality of cancer care received had changed during the pandemic.
-----
Conclusions: In the first few months of the pandemic, Croatia had a favourable epidemiological situation. However, 25% of patients with cancer reported that the pandemic affected cancer treatment and the quality of cancer care